Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Volatile and Thermally Stable Polymeric Tin Trifluoroacetates.

Bačić G, Rankine CD, Masuda JD, Wann DA, Barry ST.

Inorg Chem. 2020 Jan 21;59(2):996-1005. doi: 10.1021/acs.inorgchem.9b01308. Epub 2020 Jan 9.

PMID:
31916436
2.

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.

Marqués M, Tranchant R, Risa-Ebrí B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, Del Pozo N, Martínez de Villarreal J, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX.

Cancer Res. 2020 Feb 15;80(4):843-856. doi: 10.1158/0008-5472.CAN-19-1633. Epub 2020 Jan 7.

PMID:
31911549
3.

High-resolution 3D visualization of nanomedicine distribution in tumors.

Moss JI, Barjat H, Emmas SA, Strittmatter N, Maynard J, Goodwin RJA, Storm G, Lammers T, Puri S, Ashford MB, Barry ST.

Theranostics. 2020 Jan 1;10(2):880-897. doi: 10.7150/thno.37178. eCollection 2020.

4.

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.

Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, Bell S, Staniszewska AD, Sandin LC, Barry ST, Watkins A, Carnevalli LS, Hardaker EL.

J Immunother Cancer. 2019 Nov 28;7(1):328. doi: 10.1186/s40425-019-0794-7.

5.

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.

Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, Wouters VM, Roper J, Kendall TJ, Roxburgh CS, Horgan PG, Nixon C, Nourse C, Gunzer M, Clark W, Hedley A, Yilmaz OH, Rashid M, Bailey P, Biankin AV, Campbell AD, Adams DJ, Barry ST, Steele CW, Medema JP, Sansom OJ.

Cancer Cell. 2019 Sep 16;36(3):319-336.e7. doi: 10.1016/j.ccell.2019.08.003.

6.

Plasma-Enhanced Atomic Layer Deposition of Nanostructured Gold Near Room Temperature.

Van Daele M, Griffiths MBE, Raza A, Minjauw MM, Solano E, Feng JY, Ramachandran RK, Clemmen S, Baets R, Barry ST, Detavernier C, Dendooven J.

ACS Appl Mater Interfaces. 2019 Oct 9;11(40):37229-37238. doi: 10.1021/acsami.9b10848. Epub 2019 Sep 26.

PMID:
31523948
7.

The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.

Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF.

J Pathol. 2019 Nov;249(3):332-342. doi: 10.1002/path.5320. Epub 2019 Jul 30.

8.

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.

Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST.

Mol Cancer Ther. 2019 May;18(5):909-919. doi: 10.1158/1535-7163.MCT-18-0577. Epub 2019 Mar 14.

PMID:
30872381
9.

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.

Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, Mooney L, Hughes A, Jarvis L, Staniszewska A, Crafter C, Sidders B, Hardaker E, Hudson K, Barry ST.

J Immunother Cancer. 2018 Dec 27;6(1):158. doi: 10.1186/s40425-018-0457-0.

10.

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ.

Mol Pharmacol. 2019 Feb;95(2):222-234. doi: 10.1124/mol.118.112946. Epub 2018 Nov 20.

PMID:
30459156
11.

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr.

Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.

12.

TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence.

Bird TG, Müller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, Lu WY, Jamieson T, Govaere O, Campbell AD, Ferreira-Gonzalez S, Cole AM, Hay T, Simpson KJ, Clark W, Hedley A, Clarke M, Gentaz P, Nixon C, Bryce S, Kiourtis C, Sprangers J, Nibbs RJB, Van Rooijen N, Bartholin L, McGreal SR, Apte U, Barry ST, Iredale JP, Clarke AR, Serrano M, Roskams TA, Sansom OJ, Forbes SJ.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaan1230. doi: 10.1126/scitranslmed.aan1230.

13.

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.

Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, Eberlein C, Lenaghan C, Polanski R, Avivar-Valderas A, Cumberbatch M, Klinowska T, Critchlow SE, Cruzalegui F, Barry ST.

Mol Cancer Ther. 2018 Nov;17(11):2309-2319. doi: 10.1158/1535-7163.MCT-18-0183. Epub 2018 Aug 10.

14.

Designing Stability into Thermally Reactive Plumbylenes.

Bačić G, Zanders D, Mallick B, Devi A, Barry ST.

Inorg Chem. 2018 Jul 16;57(14):8218-8226. doi: 10.1021/acs.inorgchem.8b00719. Epub 2018 Jun 26.

PMID:
29943579
15.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

16.

Passivation of Plasmonic Colors on Bulk Silver by Atomic Layer Deposition of Aluminum Oxide.

Guay JM, Killaire G, Gordon PG, Barry ST, Berini P, Weck A.

Langmuir. 2018 May 1;34(17):4998-5010. doi: 10.1021/acs.langmuir.8b00210. Epub 2018 Apr 16.

PMID:
29570308
17.

The Chemistry of Inorganic Precursors during the Chemical Deposition of Films on Solid Surfaces.

Barry ST, Teplyakov AV, Zaera F.

Acc Chem Res. 2018 Mar 20;51(3):800-809. doi: 10.1021/acs.accounts.8b00012. Epub 2018 Feb 28.

PMID:
29489341
18.

Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?

Little RA, Barjat H, Hare JI, Jenner M, Watson Y, Cheung S, Holliday K, Zhang W, O'Connor JPB, Barry ST, Puri S, Parker GJM, Waterton JC.

Magn Reson Imaging. 2018 Feb;46:98-105. doi: 10.1016/j.mri.2017.11.008. Epub 2017 Nov 14.

19.

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.

Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling J, Staniszewska A, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST.

Clin Cancer Res. 2017 Dec 15;23(24):7584-7595. doi: 10.1158/1078-0432.CCR-17-0676. Epub 2017 Oct 2.

20.

Developing PreDICT - a fully integrated data platform for preclinical in vivo data: learning from experience.

Jones RDO, Cooke M, Hinchliffe J, Morley J, Barry ST.

Drug Discov Today. 2017 Oct;22(10):1539-1546. doi: 10.1016/j.drudis.2017.07.014. Epub 2017 Aug 9. Review.

PMID:
28800878
21.

TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis.

Cammareri P, Vincent DF, Hodder MC, Ridgway RA, Murgia C, Nobis M, Campbell AD, Varga J, Huels DJ, Subramani C, Prescott KLH, Nixon C, Hedley A, Barry ST, Greten FR, Inman GJ, Sansom OJ.

Cell Death Differ. 2017 Oct;24(10):1681-1693. doi: 10.1038/cdd.2017.92. Epub 2017 Jun 16.

22.

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.

Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN, Hattersley M, Wen S, Curtis NJ, Pilling JE, Pease EJ, Barry ST.

Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14.

23.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

PMID:
28202458
24.

Automated image analysis of intra-tumoral and peripheral endocrine organ vascular bed regression using 'Fibrelength' as a novel structural biomarker.

Hargreaves A, Bigley A, Price S, Kendrew J, Barry ST.

J Appl Toxicol. 2017 Aug;37(8):902-912. doi: 10.1002/jat.3438. Epub 2017 Feb 10.

PMID:
28186326
25.

Surface chemistry of group 11 atomic layer deposition precursors on silica using solid-state nuclear magnetic resonance spectroscopy.

Pallister PJ, Barry ST.

J Chem Phys. 2017 Feb 7;146(5):052812. doi: 10.1063/1.4968021.

PMID:
28178840
26.

Effect of the nature of the substrate on the surface chemistry of atomic layer deposition precursors.

Yao Y, Coyle JP, Barry ST, Zaera F.

J Chem Phys. 2017 Feb 7;146(5):052806. doi: 10.1063/1.4966201.

PMID:
28178813
27.

Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.

England RM, Hare JI, Barnes J, Wilson J, Smith A, Strittmatter N, Kemmitt PD, Waring MJ, Barry ST, Alexander C, Ashford MB.

J Control Release. 2017 Feb 10;247:73-85. doi: 10.1016/j.jconrel.2016.12.034. Epub 2016 Dec 30.

PMID:
28043863
28.

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP.

Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6.

29.

The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.

Maynard J, Emmas SA, Blé FX, Barjat H, Lawrie E, Hancox U, Oakes D, Polanska UM, Barry ST.

EJNMMI Res. 2016 Dec;6(1):62. doi: 10.1186/s13550-016-0220-9. Epub 2016 Aug 11.

30.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP.

Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2.

31.

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST.

Adv Drug Deliv Rev. 2017 Jan 1;108:25-38. doi: 10.1016/j.addr.2016.04.025. Epub 2016 Apr 29. Review.

32.

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, Davies BR.

Oncotarget. 2016 Apr 19;7(16):22128-39. doi: 10.18632/oncotarget.8031.

33.

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.

Bradford JR, Wappett M, Beran G, Logie A, Delpuech O, Brown H, Boros J, Camp NJ, McEwen R, Mazzola AM, D'Cruz C, Barry ST.

Oncotarget. 2016 Apr 12;7(15):20773-87. doi: 10.18632/oncotarget.8014.

34.

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.

Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST.

Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355.

35.

Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition.

Horton ER, Humphries JD, Stutchbury B, Jacquemet G, Ballestrem C, Barry ST, Humphries MJ.

J Cell Biol. 2016 Feb 1;212(3):349-64. doi: 10.1083/jcb.201508080.

36.

Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression.

Estrada MF, Rebelo SP, Davies EJ, Pinto MT, Pereira H, Santo VE, Smalley MJ, Barry ST, Gualda EJ, Alves PM, Anderson E, Brito C.

Biomaterials. 2016 Feb;78:50-61. doi: 10.1016/j.biomaterials.2015.11.030. Epub 2015 Nov 19.

37.

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices.

Davies EJ, Dong M, Gutekunst M, Närhi K, van Zoggel HJ, Blom S, Nagaraj A, Metsalu T, Oswald E, Erkens-Schulze S, Delgado San Martin JA, Turkki R, Wedge SR, af Hällström TM, Schueler J, van Weerden WM, Verschuren EW, Barry ST, van der Kuip H, Hickman JA.

Sci Rep. 2015 Dec 9;5:17187. doi: 10.1038/srep17187.

38.

Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

Pommier AJ, Farren M, Patel B, Wappett M, Michopoulos F, Smith NR, Kendrew J, Frith J, Huby R, Eberlein C, Campbell H, Womack C, Smith PD, Robertson J, Morgan S, Critchlow SE, Barry ST.

Cell Metab. 2016 Jan 12;23(1):77-93. doi: 10.1016/j.cmet.2015.10.015. Epub 2015 Nov 25.

39.

PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.

Hall AP, Ashton S, Horner J, Wilson Z, Reens J, Richmond GH, Barry ST, Wedge SR.

Toxicol Pathol. 2016 Jan;44(1):98-111. doi: 10.1177/0192623315613452. Epub 2015 Nov 3.

PMID:
26534939
40.

The effect of ALD-grown Al₂O₃ on the refractive index sensitivity of CVD gold-coated optical fiber sensors.

Mandia DJ, Zhou W, Ward MJ, Joress H, Sims JJ, Giorgi JB, Albert J, Barry ST.

Nanotechnology. 2015 Oct 30;26(43):434002. doi: 10.1088/0957-4484/26/43/434002. Epub 2015 Oct 5.

PMID:
26437035
41.

Absolute near-infrared refractometry with a calibrated tilted fiber Bragg grating.

Zhou W, Mandia DJ, Barry ST, Albert J.

Opt Lett. 2015 Apr 15;40(8):1713-6. doi: 10.1364/OL.40.001713.

PMID:
25872055
42.

Tumour stromal morphology impacts nanomedicine cytotoxicity in patient-derived xenografts.

Delgado San Martin JA, Hare JI, Yates JW, Barry ST.

Nanomedicine. 2015 Jul;11(5):1247-52. doi: 10.1016/j.nano.2015.02.007. Epub 2015 Mar 6.

PMID:
25752857
43.

WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.

Boulter L, Guest RV, Kendall TJ, Wilson DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N, Barry ST, Wigmore SJ, Sansom OJ, Forbes SJ.

J Clin Invest. 2015 Mar 2;125(3):1269-85. doi: 10.1172/JCI76452. Epub 2015 Feb 17.

44.

Anisotropic effective permittivity of an ultrathin gold coating on optical fiber in air, water and saline solutions.

Zhou W, Mandia DJ, Barry ST, Albert J.

Opt Express. 2014 Dec 29;22(26):31665-76. doi: 10.1364/OE.22.031665.

PMID:
25607137
45.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.

Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

46.

Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Rossant CJ, Carroll D, Huang L, Elvin J, Neal F, Walker E, Benschop JJ, Kim EE, Barry ST, Vaughan TJ.

MAbs. 2014;6(6):1425-38. doi: 10.4161/mabs.34376.

47.

Mechanisms that influence tumour response to VEGF-pathway inhibitors.

Smith NR, Wedge SR, Pommier A, Barry ST.

Biochem Soc Trans. 2014 Dec;42(6):1601-7. doi: 10.1042/BST20140261. Review.

PMID:
25399577
48.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

49.

Tumor stromal phenotypes define VEGF sensitivity--response.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2014 Oct 1;20(19):5141. doi: 10.1158/1078-0432.CCR-14-0681. No abstract available.

50.

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.

Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.

PMID:
25220373

Supplemental Content

Loading ...
Support Center